Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous page Next page

We aim to cover the following topics:

  1. The mechanism of action of PARP inhibition and its role in the treatment of prostate cancer.
  2. Testing strategies to identify DNA Damage Repair (DDR) mutations in prostate cancer, and their prevalence and clinical relevance.
    • How to perform genetic counselling.
    • The difference between different genomic tests.
  3. Clinical efficacy and safety profile of PARP inhibitors for patients with prostate cancer.
    • Patient selection using genetic/genomic testing results.
    • The management of adverse events.
  4. The place of PARP inhibition in the prostate cancer treatment pathway and future developments.
    • The PARP inhibitors in development for prostate cancer.
    • The potential combination strategies with PARP inhibitors.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings